デノスマブは腹膜透析患者の骨密度を増加させたが、著しい血清カルシウム変動を引き起こした。
Denosumab increased bone mineral density but caused marked serum calcium fluctuations in a patient undergoing peritoneal dialysis.
Yamada Shunsuke, Enomoto Soma, Matsuo Kana, Sonezaki Yusuke ほか — CEN case reports
AI要約
デノスマブは、腹膜透析中の患者の骨粗鬆症治療に用いられ、骨密度を改善しました。しかし、予防策を講じたにもかかわらず、血中カルシウム値が著しく変動し、低カルシウム血症から高カルシウム血症へと移行しました。この症例は、デノスマブ投与後の腹膜透析患者におけるカルシウム管理には、厳密なモニタリングと特定の治療プロトコルが不可欠であることを示しています。
AI生成の要約です — 原文を読む
Abstract(原文)
Denosumab is increasingly used to treat osteoporosis in patients with advanced kidney disease, but clinically significant disturbances in calcium homeostasis remain a major concern. We report a peritoneal dialysis (PD) case in which denosumab administration was followed by pronounced calcium fluctuations requiring medication management. A 56-year-old woman with end-stage kidney disease due to lupus nephritis, receiving prednisolone (5 mg/day), had been on continuous ambulatory PD (1.5-L exchanges three times daily) for 5 years. Baseline intact parathyroid hormone was 176 pg/mL. Osteoporosis was confirmed by dual-energy X-ray absorptiometry (lumbar spine 68% and femoral neck 58% of the young adult mean [YAM]). Denosumab 60 mg was administered, and BMD increased within 10 months to 78% YAM at the lumbar spine and 77% YAM at the femoral neck (same facility, identical DXA equipment). To mitigate hypocalcemia, dialysate calcium was pre-emptively increased to two 3.5-mEq/L and one 2.5-mEq/L bags per day (albumin-corrected calcium 9.5 mg/dL at dosing). Nonetheless, symptomatic hypocalcemia developed (nadir 7.8 mg/dL on day 7), prompting escalation to three 3.5-mEq/L bags with intensified vitamin D therapy and calcium supplementation. Serum calcium then overshot, peaking at 13.8 mg/dL on day 29; therapy was de-escalated and calcium stabilized. This case highlights that while daily dialysate calcium exposure in PD may buffer early hypocalcemia, concurrent escalation of dialysate calcium, vitamin D therapy, and calcium supplementation can precipitate overshoot hypercalcemia. Frequent monitoring and staged, stepwise prescription changes during the first month after denosumab are essential. Standardized PD-specific post-denosumab calcium management protocols are urgently needed.
このコラムに関連する書籍
Amazonのアソシエイトとして、栄養DBは適格販売により収入を得ています。また、楽天アフィリエイトプログラムに参加しています。
出典: PubMed (PMID: 42377652)。AI要約は情報提供のみを目的とし、医療的アドバイスを構成するものではありません。